Free Trial

Burrill Institutional Research Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Burrill Institutional Research. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Burrill Institutional Research.

MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyCurrent PriceRating DateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActions
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$117.99
-1.4%
7/24/2013Downgraded byBurrill Institutional Research-Outperform -> Market Perform$39.00N/AView details for Burrill Institutional Research rating of Sarepta Therapeutics (NASDAQ:SRPT) on 7/24/2013
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$117.99
-1.4%
5/13/2013Reiterated byBurrill Institutional Research-Outperform$39.00N/AView details for Burrill Institutional Research rating of Sarepta Therapeutics (NASDAQ:SRPT) on 5/13/2013
Novavax, Inc. stock logo
NVAX
Novavax
$12.68
-2.8%
3/19/2013Initiated byBurrill Institutional Research-OutperformN/AView details for Burrill Institutional Research rating of Novavax (NASDAQ:NVAX) on 3/19/2013
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$117.99
-1.4%
3/8/2013Target Lowered byBurrill Institutional Research-Outperform$54.00 -> $39.00N/AView details for Burrill Institutional Research rating of Sarepta Therapeutics (NASDAQ:SRPT) on 3/8/2013
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$0.79
-2.5%
2/19/2013Initiated byBurrill Institutional Research-Outperform$28.00N/AView details for Burrill Institutional Research rating of Sangamo Therapeutics (NASDAQ:SGMO) on 2/19/2013
Omeros Co. stock logo
OMER
Omeros
$3.83
-1.5%
12/28/2012Target Lowered byBurrill Institutional Research-Outperform$19.00 -> $16.00N/AView details for Burrill Institutional Research rating of Omeros (NASDAQ:OMER) on 12/28/2012
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$117.99
-1.4%
11/26/2012Initiated byBurrill Institutional Research-Outperform$54.00N/AView details for Burrill Institutional Research rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/26/2012
Omeros Co. stock logo
OMER
Omeros
$3.83
-1.5%
10/15/2012Initiated byBurrill Institutional Research-Outperform$17.00N/AView details for Burrill Institutional Research rating of Omeros (NASDAQ:OMER) on 10/15/2012

MarketBeat Community Rating for Burrill Institutional Research

Community Ranking:  2.6 out of 5 (
2.6 of 5 stars)
Outperform Votes:  29,041 (Vote Outperform)
Underperform Votes:  25,810 (Vote Underperform)
Total Votes:  54,851
MarketBeat's community ratings are surveys of what our community members think about Burrill Institutional Research and other research firms. Vote "Outperform" if you believe Burrill Institutional Research's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Burrill Institutional Research's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.